Invention Grant
- Patent Title: RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders
-
Application No.: US15255278Application Date: 2016-09-02
-
Publication No.: US09765340B2Publication Date: 2017-09-19
- Inventor: John M. Yanni , Jon E. Chatterton , Daniel A. Gamache , Steven T. Miller
- Applicant: Arrowhead Pharmaceuticals, Inc.
- Applicant Address: US CA Pasadena
- Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee Address: US CA Pasadena
- Agent Robert Michael Teigen
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C07H21/02 ; A61K48/00 ; A61K31/7088
Abstract:
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
Public/Granted literature
- US20170051291A1 RNAi-Mediated Inhibition of Phosphodiesterase Type 4 for Treatment of CAMP-Related Ocular Disorders Public/Granted day:2017-02-23
Information query
IPC分类:
